PL1663182T3 - Szybko rozpuszczalna formulacja cynakalcetu HCI - Google Patents

Szybko rozpuszczalna formulacja cynakalcetu HCI

Info

Publication number
PL1663182T3
PL1663182T3 PL04781429T PL04781429T PL1663182T3 PL 1663182 T3 PL1663182 T3 PL 1663182T3 PL 04781429 T PL04781429 T PL 04781429T PL 04781429 T PL04781429 T PL 04781429T PL 1663182 T3 PL1663182 T3 PL 1663182T3
Authority
PL
Poland
Prior art keywords
rapid dissolution
cinacalcet hcl
dissolution formulation
formulation
cinacalcet
Prior art date
Application number
PL04781429T
Other languages
English (en)
Other versions
PL1663182T5 (pl
Inventor
Francisco J Alvarez
Glen Gary Lawrence
Hung-Ren H Lin
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1663182(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PL1663182T3 publication Critical patent/PL1663182T3/pl
Publication of PL1663182T5 publication Critical patent/PL1663182T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04781429T 2003-09-12 2004-09-10 Szybko rozpuszczalna formulacja cynakalcetu HCI PL1663182T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound
EP04781429.8A EP1663182B2 (en) 2003-09-12 2004-09-10 RAPID DISSOLUTION FORMULATION OF CINACALCET HCl

Publications (2)

Publication Number Publication Date
PL1663182T3 true PL1663182T3 (pl) 2013-06-28
PL1663182T5 PL1663182T5 (pl) 2020-07-27

Family

ID=34434844

Family Applications (6)

Application Number Title Priority Date Filing Date
PL17185704T PL3260117T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL18175499T PL3395340T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL18175495T PL3395338T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL18175497T PL3395339T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL04781429T PL1663182T5 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczalna formulacja cynakalcetu HCI
PL14163366T PL2821067T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczający się preparat cynakalcetu

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PL17185704T PL3260117T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL18175499T PL3395340T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL18175495T PL3395338T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL18175497T PL3395339T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14163366T PL2821067T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczający się preparat cynakalcetu

Country Status (30)

Country Link
US (7) US7829595B2 (pl)
EP (8) EP3395340B8 (pl)
JP (3) JP5026077B2 (pl)
KR (1) KR101332058B1 (pl)
CN (1) CN1946382B (pl)
AR (1) AR045637A1 (pl)
AU (1) AU2004279318C1 (pl)
BR (2) BR122018013029B1 (pl)
CA (1) CA2536487C (pl)
CY (5) CY1119609T1 (pl)
DE (1) DE19164145T1 (pl)
DK (6) DK3395340T3 (pl)
EA (1) EA013425B1 (pl)
ES (7) ES2735226T3 (pl)
HR (1) HRP20130114T4 (pl)
HU (5) HUE043958T2 (pl)
IL (1) IL173737A (pl)
IS (1) IS3027B (pl)
MX (1) MXPA06002616A (pl)
MY (1) MY142046A (pl)
NO (1) NO335739B1 (pl)
NZ (1) NZ545498A (pl)
PL (6) PL3260117T3 (pl)
PT (6) PT3395339T (pl)
SG (1) SG146608A1 (pl)
SI (6) SI3395338T1 (pl)
TR (4) TR201910180T4 (pl)
TW (1) TWI344363B (pl)
WO (1) WO2005034928A1 (pl)
ZA (1) ZA200602710B (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2006125026A2 (en) * 2005-05-16 2006-11-23 Teva Pharmaceutical Industries, Ltd. Process for preparing cinacalcet hydrochloride
JP2008507567A (ja) * 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド 非晶性シナカルセト塩酸塩及びその調製
EP1883618B1 (en) * 2005-05-23 2009-10-14 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
CA2620469C (en) * 2005-09-02 2014-04-01 Amgen Inc. Methods of modulating intestinal fluid balance
EP1828098A1 (en) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
MX2008012061A (es) * 2006-03-23 2008-12-17 Amgen Inc Metodos y composiciones para elaborar y utilizar polimorfos de cinacalcet.
TW200808297A (en) * 2006-04-27 2008-02-16 Teva Pharma Process for the preparation of cinacalcet base
EP1928817A1 (en) * 2006-04-27 2008-06-11 Teva Pharmaceutical Industries Ltd Process for the preparation of cinacalcet base
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
WO2008027522A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calicum receptor-active compound
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20120009258A1 (en) * 2008-09-25 2012-01-12 Ratiopharm Gmbh Compacted cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
JP2012528084A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
JP6245983B2 (ja) 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
EP2642980B8 (en) * 2010-11-23 2020-06-03 Amgen Inc. Pediatric formulation
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
RU2013128981A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении чувствительных к кальцию рецепторов
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
PL2730279T3 (pl) 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
ES2737756T3 (es) * 2012-12-21 2020-01-15 Synthon Bv Composición de comprimido que comprende clorhidrato de cinacalcet
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2014207691A1 (en) 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
EP3668493A4 (en) * 2017-08-16 2021-08-25 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS WITH CINACALCET HYDROCHLORIDE AND ONE OR MORE BINDERS
EP3773533A1 (en) 2018-03-30 2021-02-17 FTF Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
CA3172050A1 (en) * 2020-02-29 2021-09-02 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
EP0315249A1 (en) 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
IL92484A0 (en) 1988-11-30 1990-08-31 Schering Corp Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE69233586T2 (de) 1991-08-23 2006-09-28 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-Rezeptor aktive Verbindungen
AU702629B2 (en) 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
AU3777093A (en) 1993-02-23 1994-09-14 Brigham And Women's Hospital Calcium receptor-active molecules
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
JP4117506B2 (ja) 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
WO1998001417A1 (en) 1996-07-08 1998-01-15 Kirin Beer Kabushiki Kaisha Calcium receptor-active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
EP1058538B9 (en) 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
AU760889B2 (en) 1998-10-14 2003-05-22 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
UA74775C2 (en) * 1998-11-23 2006-02-15 Monsanto Ci High concentrated aqueous composition of the monoethanolammonium salt of n-phosphonomethylglycine and a method to control undesired plants
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
CZ20022140A3 (cs) * 1999-12-22 2002-11-13 Pharmacia Corporation Formulace inhibitoru cyklooxygenázy -2 s postupným uvolňováním
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
WO2002024230A1 (en) 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (pl) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
AU2003272767A1 (en) 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
ES2358269T3 (es) 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
EP2252901A4 (en) 2008-03-11 2012-01-25 Univ Western Ontario SYSTEM AND METHOD FOR MAGNETIC RESONANCE IMAGING

Also Published As

Publication number Publication date
SI2821067T1 (en) 2018-03-30
US9375405B2 (en) 2016-06-28
ZA200602710B (en) 2007-04-25
CY1119609T1 (el) 2018-04-04
PL2821067T3 (pl) 2018-02-28
SI3395340T1 (sl) 2019-08-30
ES2734057T3 (es) 2019-12-04
US7829595B2 (en) 2010-11-09
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
HUE044279T2 (hu) 2019-10-28
EP2821067A1 (en) 2015-01-07
EP3395338A1 (en) 2018-10-31
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
TWI344363B (en) 2011-07-01
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (xx) 2013-03-31
EA013425B1 (ru) 2010-04-30
EP1663182B2 (en) 2019-11-20
TW200518743A (en) 2005-06-16
DK3260117T3 (da) 2019-07-01
CN1946382B (zh) 2010-12-08
EP2821067B1 (en) 2017-10-25
EP3395339A1 (en) 2018-10-31
IL173737A (en) 2012-04-30
EP3395340B8 (en) 2019-12-11
TR201910447T4 (tr) 2019-08-21
CA2536487A1 (en) 2005-04-21
BRPI0414254A (pt) 2006-11-07
IS3027B (is) 2021-03-15
EP3260117B1 (en) 2019-04-17
EP3395338B1 (en) 2019-05-01
PT3395339T (pt) 2019-07-15
JP5940120B2 (ja) 2016-06-29
SG146608A1 (en) 2008-10-30
NO335739B1 (no) 2015-02-02
ES2735226T3 (es) 2019-12-17
PT1663182E (pt) 2013-03-14
NZ545498A (en) 2010-04-30
DE19164145T1 (de) 2021-04-29
DK3395340T3 (da) 2019-07-15
BRPI0414254B8 (pt) 2021-05-25
SI3260117T1 (sl) 2019-08-30
SI1663182T2 (sl) 2020-02-28
EP2316442A1 (en) 2011-05-04
EP3260117A1 (en) 2017-12-27
JP5849015B2 (ja) 2016-01-27
SI1663182T1 (sl) 2013-05-31
ES2401769T3 (es) 2013-04-24
CY1121814T1 (el) 2020-07-31
CY1122259T1 (el) 2020-11-25
CA2536487C (en) 2011-10-25
PL3395338T3 (pl) 2019-10-31
BRPI0414254B1 (pt) 2021-03-02
DK3395338T3 (da) 2019-07-22
TR201910177T4 (tr) 2019-08-21
DK1663182T3 (da) 2013-04-15
SI3395339T1 (sl) 2019-08-30
JP2007505108A (ja) 2007-03-08
ES2655435T3 (es) 2018-02-20
EA200600566A1 (ru) 2006-08-25
MY142046A (en) 2010-08-30
HUE035596T2 (en) 2018-05-28
PT2821067T (pt) 2017-12-01
TR201910180T4 (tr) 2019-07-22
EP3578175B1 (en) 2022-11-30
PL3395339T3 (pl) 2019-09-30
KR20070017460A (ko) 2007-02-12
JP5026077B2 (ja) 2012-09-12
EP3395340B1 (en) 2019-04-17
AU2004279318A1 (en) 2005-04-21
PT3395338T (pt) 2019-07-23
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
AU2004279318C1 (en) 2020-06-25
PT3395340T (pt) 2019-07-15
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
EP3260117B8 (en) 2019-11-27
NO20061640L (no) 2006-06-12
PL3395340T3 (pl) 2019-10-31
DK1663182T4 (da) 2020-02-17
IL173737A0 (en) 2006-07-05
ES2737348T3 (es) 2020-01-13
SI3395338T1 (sl) 2019-08-30
US20180243238A1 (en) 2018-08-30
EP1663182A1 (en) 2006-06-07
JP2012197280A (ja) 2012-10-18
DK3395339T3 (da) 2019-07-22
US20190117592A1 (en) 2019-04-25
CN1946382A (zh) 2007-04-11
EP3395339B1 (en) 2019-04-17
US20210052518A1 (en) 2021-02-25
PT3260117T (pt) 2019-07-04
HUE044822T2 (hu) 2019-11-28
TR201909267T4 (tr) 2019-07-22
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
CY1121812T1 (el) 2020-07-31
PL1663182T5 (pl) 2020-07-27
WO2005034928A1 (en) 2005-04-21
AU2004279318B2 (en) 2010-02-25
BR122018013029B1 (pt) 2022-04-12
HUE045411T2 (hu) 2019-12-30
IS8324A (is) 2006-02-23
US20200222340A1 (en) 2020-07-16
US20110136915A1 (en) 2011-06-09
AR045637A1 (es) 2005-11-02
PL3260117T3 (pl) 2019-10-31
ES2812198T1 (es) 2021-03-16
EP3395339B8 (en) 2019-12-11
US20160338975A1 (en) 2016-11-24
US20050147669A1 (en) 2005-07-07
ES2735216T3 (es) 2019-12-17

Similar Documents

Publication Publication Date Title
SI1663182T1 (sl) Hitro raztapljajoča se formulacija cinakalceta HCI
EP1684689A4 (en) VENLAFAXINE PREPARATION WITH PROLONGED RELEASE
GB0323908D0 (en) Pharmaceutical foam formulation
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
EG24479A (en) Modified release pharmaceutical formulation
GB0318448D0 (en) Formulation
GB0316206D0 (en) Pharmaceutical formulation
IL165069A0 (en) Immediate release pharmaceutical formulation
IL164077A0 (en) Sustained release formulation of tramadol
GB0312195D0 (en) Formulation
GB0320522D0 (en) Formulation
GB0303876D0 (en) Formulation
GB0310881D0 (en) Pharmaceutical formulation
GB0318663D0 (en) Rolling formulation
IL159780A0 (en) Extended release venlafaxine tablet formulation
GB0308978D0 (en) Formulation
GB0316538D0 (en) Formulation
ZA200510326B (en) Dimeticone-containing sustaned formulation
GB0302435D0 (en) Pharmaceutical formulation